Additionally, gemcitabine treatment in pancreas cancer patients showed no significant changes in proportions of T and B-cells including CD86 and CD80 APCs or CD4+, CD25+ T-cells [36]. This evidence concerns the gene CD80 and pancreatic neoplasm.